Cardiovascular Research: Past, Present and Future
Journal Title: Heart Research – Open Journal - Year 2015, Vol 2, Issue 2
Abstract
Cardiovascular disease remains a leading cause of death and significant burden on healthcare systems worldwide. While interventional and preventative medicine has considerably changed the face of clinical practice, at the molecular level, treatment has not altered in recent decades and is still directed towards alleviating symptoms or mitigating the underlying cause rather than regenerating damaged heart muscle. This is surprising, given the explosion of research in this area in the 1970’s, and the fact that research output has continued to increase exponentially. With the incidence of heart failure on the rise, a trend predicted to continue, it is imperative that treatment strategies are improved. The development and adoption of molecular interventions might therefore present the most fruitful avenue in providing the greatest impact on mortality rates. This commentary aims to reflect on the earliest documented studies of human cardiovascular physiology, to surgical interventions in the 12th, to the first molecular studies in the 20th, to current pharmacological treatments. With this knowledge in mind, the future of molecular approaches in treating heart failure and cardiovascular conditions will be considered.
Authors and Affiliations
Lorna R. Fiedler
Keywords
Related Articles
- EP ID EP556830
- DOI 10.17140/HROJ-2-112
- Views 123
- Downloads 0
Cardioprotective Effect of Losartan Alone or in Combination with Remote Ischemic Preconditioning on the Biochemical Changes Induced by Ischemic/Reperfusion Injury in a Mutual Prospective Study with a Clinical and Experimental Animal Arm
Background and Aims: Losartan is an angiotensin receptor II antagonist used clinically to reduce blood pressure and treat hypertension or hypertrophic cardiomyopathy. It is also proposed to suppress cardiac injury follow...
Impact of Resistance Training on Quality of Life and Ischemia Modified Albumin Levels in Men with Cardiovascular Risk Factors
Purpose: There are limited data concerning the effects of Resistance Training (RT) on the components of Quality of Life (QOL) and Ischemia Modified Albumin (IMA) serum levels, even though QOL is an important characterist...
Treatment of Cardiac Hemochromatosis
Treatment of iron-overload states is important to prevent or reverse cardiac dysfunction.1-5 Removal of excess iron from the tissues in these patients reduces generation of free radicals, decreasing organ damage.6,7 Remo...
Pharmacological Agents in the Clinic: Trial and Error
Following an explosion of molecular and cellular research in the last 50 years, the study of specific molecular targets in the context of heart failure has generated much excitement. With the incidence of heart failure r...
Combination Therapy With Beta Blocker and Inotrope in Decompensated Heart Failure: A Clinical Observation
Inotropic support is contemplated in the presence of ongoing end-organ hypoperfusion or refractory symptoms in decompensated heart failure (DHF). However, inotropic agents may cause tachycardia leading to increased myoca...